Sensorion Gets Positive Recommendation for Clinical Trial of Drug Candidate for Cisplatin-Induced Ototoxicity
Sensorion was recommended to continue the study of a drug candidate for the prevention of Cisplatin-Induced Ototoxicity (CIO).
Sensorion was recommended to continue the study of a drug candidate for the prevention of Cisplatin-Induced Ototoxicity (CIO).
Fennec Pharmaceuticals Inc announced that the FDA has accepted for filing the resubmission of its New Drug Application (NDA) for PEDMARK for the prevention of ototoxicity induced by cisplatin chemotherapy in patients one month to < 18 years of age with localized, non-metastatic, solid tumors.
Nearly 2.5 billion people worldwide ─ or 1 in 4 people ─ will be living with some degree of hearing loss by 2050, warns the World Health Organization’s (WHO) first World Report on Hearing.
Repurposing approved compounds carries both opportunities and risks, including a high risk of ototoxicity based on existing data on the drug classes under consideration.
Read MoreResearchers identified 41 people with opioid exposure who experienced full or partial hearing loss or tinnitus, likely caused by toxicity to the ear. More than half had used heroin, followed by oxycodone, methadone, and tramadol; 88% had only one known exposure.
Read MoreAccording to the CRL, after recent completion of a pre-approval inspection of the manufacturing facility of our drug product manufacturer, the FDA identified deficiencies resulting in a Form 483, which is a list of conditions or practices that are required to be resolved prior to the approval of PEDMARK.
Read MoreFindings show that survivors with severe hearing loss are at a significantly increased risk for neurocognitive deficits, independent of what type of therapy they receive.
Read MoreIn an article on “Forbes,” professor and journalist Bruce Y. Lee reviews the evidence currently available regarding the link between COVID-19 and hearing loss.
Read MorePEDMARK is said to be an investigational drug for the prevention of ototoxicity induced by cisplatin chemotherapy in patients one month to <18 years of age with localized, non-metastatic, solid tumors.
Read MoreSensorion (Paris:ALSEN) (FR0012596468 – ALSEN), a clinical-stage biotech company which specializes...
Read MoreResearchers involved with a qualitative study published in Cancer concluded that clinicians play...
Read MoreFor those companies or individuals who have a concern about hearing damage that may have been...
Read MoreThe proteins, described in a report published June 12 in “eLife,” may hold a key to future therapies to restore hearing in people with irreversible deafness. An article summarizing the research was published on the Johns Hopkins Medicine website.
Read MoreSENS-401 is under development in the treatment of Sudden Sensorineural Hearing Loss (or SSNHL).
Read MoreSENS-401 is under development in the treatment of Sudden Sensorineural Hearing Loss (or SSNHL).
Read MoreSENS-401 is under development in the treatment of Sudden Sensorineural Hearing Loss (or SSNHL).
Read MoreThe book describes major advances in our understanding of the pathogenic processes underlying various forms of hearing loss and the emergence of treatments for deafness.
Read MoreIn Phase 1, CILcare was reportedly able to correlate electrophysiology, manganese-enhanced magnetic resonance imaging (MEMRI), and behavioral assessments that define a preclinical model for detecting tinnitus. In Phase 2, CILcare will adapt the preclinical model to humans.
Read More